MAIA Reports $33M Capital Raise, Funds Pivotal Phase 3 Telomere Therapy Trial, FDA Fast Track for NSCLC
MAIA Biotechnology, Inc. · PHARMACEUTICAL PREPARATIONS · Now $1.30
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS